FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer

Oncology

Volumn 70, Issue 5, 2007, Pages 345-350

  Petrioli, Roberto ^a   Paolelli, Loretta ^a   Marsili, Stefania ^a   Civitelli, Serenella ^b   Francini, Edoardo ^a   Cioppa, Tommaso ^b   Roviello, Franco ^b   Nettuno, Raffaele ^c   Intrivici, Chiara ^d   Tanzini, Gabriello ^b   Lorenzi, Marco ^b   Francini, Guido ^a,b  

^a Section of Medical Oncology   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c S Felice Hospital   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Capecitabine; Colorectal cancer; First line chemotherapy; Neurotoxicity; Oxaliplatin

Indexed keywords

CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; OXALIPLATIN; SEROTONIN ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; FEMALE; FEVER; FUNCTIONAL DISEASE; HAND FOOT SYNDROME; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; ORAL REHYDRATION THERAPY; PARESTHESIA; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; ORGANOPLATINUM COMPOUNDS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33846124279     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098107     Document Type: Article

References (23)

1. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
2. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M, Oncology Multidisciplinary Research Group (GERCOR): High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as secondline therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 2001;37:1000-1005.
3. Shields AF, Zalupski MM, Marshall JL, Meropol NJ: Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine. Cancer 2004;100:531-537.
4. Van Cutsem E, Twelves C, Cassidy J, Allman D, Baietta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P:Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
5. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fegerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
6. Di Francesco AM, Ruggiero A, Riccardi R: Cellular and molecular aspects of drugs of the future:oxaliplatin. Cell Mol Life Sci 2002;59:1914-1927.
7. Cassidy J, Misset JL: Oxaliplatin-related side effects:characteristics and management. Semin Oncol 2002;29(suppl 15):11-20.
8. Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29(suppl 15):21-33.
9. Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Clarke S: Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 2005;92:832-837.
10. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
11. Tournigand C, Cervantes A, Figer A, Lledo G, Flesh M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andrè T, Tabah-Fisch I, De Gramont A: OPTIMOX1: a randomised study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
12. Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bannamoun M, Mabro M, Artru P, Louvet C, De Gramont A, GERCOR: OPTIMOX2, a large randomised phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. ASCO 2006;24:3504.
13. WHO criteria: WHO handbook for reporting results of cancer treatment. Geneva, World Health Organization, 1979, Offset Publication No. 48.
14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
15. Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85:2532-2540.
16. Gamelin L, Boisdron-Celle, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055- 4061.
17. Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004;90:306-309.
18. Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, Busquier I, Campos JM, Perez-Enguix D, Balcells M: FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2005;5:263-267.
19. Liu G, Franssen E, Fitch MI, Warner E: Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
20. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-analysis group in cancer: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-3775.
21. Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, Louvet C, de Gramont A: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004;15:1210-1214.
22. Maughan TS, James RD, Kerr DJ, Ledermann J, Seymour M, Topham C, McArdle C, Cain D, Stephens R: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 2003;361:457-464.
23. Plantade A, Afchain P, Tournigand C, Maindrault-Goebel F, Chibaudel B, Bourges O, Perez-Staub N, Larsen A, Louvet C, De Gramont A: Chemotherapy-free intervals (CFI) in patients with metastatic colorectal cancer (MRC). ASCO 2006;24:3581.